KR20090029299A - (7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염 - Google Patents

(7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염 Download PDF

Info

Publication number
KR20090029299A
KR20090029299A KR1020097002844A KR20097002844A KR20090029299A KR 20090029299 A KR20090029299 A KR 20090029299A KR 1020097002844 A KR1020097002844 A KR 1020097002844A KR 20097002844 A KR20097002844 A KR 20097002844A KR 20090029299 A KR20090029299 A KR 20090029299A
Authority
KR
South Korea
Prior art keywords
disorder
disorders
disease
dementia
tartrate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097002844A
Other languages
English (en)
Korean (ko)
Inventor
케빈 쿤-친 리우
유안 젱
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20090029299A publication Critical patent/KR20090029299A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097002844A 2006-07-14 2007-07-09 (7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염 Ceased KR20090029299A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83089006P 2006-07-14 2006-07-14
US60/830,890 2006-07-14

Publications (1)

Publication Number Publication Date
KR20090029299A true KR20090029299A (ko) 2009-03-20

Family

ID=38542082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002844A Ceased KR20090029299A (ko) 2006-07-14 2007-07-09 (7s)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2r)-2-메틸피페라진-1-일]-6,7-다이하이드로-5h-사이클로펜타[b]피리딘의 타르트레이트 염

Country Status (16)

Country Link
US (1) US20100004259A1 (cg-RX-API-DMAC7.html)
EP (1) EP2044029B1 (cg-RX-API-DMAC7.html)
JP (1) JP4312243B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090029299A (cg-RX-API-DMAC7.html)
CN (1) CN101506172A (cg-RX-API-DMAC7.html)
AR (1) AR062068A1 (cg-RX-API-DMAC7.html)
AT (1) ATE496894T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007274710A1 (cg-RX-API-DMAC7.html)
CA (1) CA2657640A1 (cg-RX-API-DMAC7.html)
DE (1) DE602007012254D1 (cg-RX-API-DMAC7.html)
IL (1) IL196417A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009000508A (cg-RX-API-DMAC7.html)
NO (1) NO20090667L (cg-RX-API-DMAC7.html)
TW (1) TW200821293A (cg-RX-API-DMAC7.html)
WO (1) WO2008010073A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901051B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
JP5124308B2 (ja) 2008-02-26 2013-01-23 株式会社リコー トナー、該トナーを用いた現像剤、トナー入り容器、プロセスカートリッジ、及び画像形成方法
WO2010079605A1 (ja) * 2009-01-09 2010-07-15 東レ・ファインケミカル株式会社 高純度1-ベンジル-3-アミノピロリジンの製造方法
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9993273B2 (en) 2013-01-16 2018-06-12 Mako Surgical Corp. Bone plate and tracking device using a bone plate for attaching to a patient's anatomy
CN105073054B (zh) 2013-01-16 2018-07-10 史赛克公司 指示视线误差的导航系统和方法
US10095785B2 (en) * 2013-09-30 2018-10-09 Sonos, Inc. Audio content search in a media playback system
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2016069036A1 (en) * 2014-11-01 2016-05-06 Hewlett Packard Enterprise Development Lp Dynamically updating metadata
US10537395B2 (en) 2016-05-26 2020-01-21 MAKO Surgical Group Navigation tracker with kinematic connector assembly
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
JP7114702B2 (ja) * 2017-07-11 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換キサンチン誘導体
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3669876A1 (en) * 2018-12-18 2020-06-24 Aelis Farma 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
WO2023248222A1 (en) * 2022-06-21 2023-12-28 Technion Research & Development Foundation Limited 5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
EP0361489A3 (en) * 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
DE4326151A1 (de) * 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (cg-RX-API-DMAC7.html) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5698766A (en) * 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US6040448A (en) * 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
US6281243B1 (en) * 1998-02-26 2001-08-28 Akzo Nobel N.V. Derivatives of azetidine and pyrrolidine
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
JP2002523451A (ja) * 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
US6681690B2 (en) * 2000-01-25 2004-01-27 Koenig & Bauer Aktiengesellschaft Sheet-fed printing press with screen-printing cylinder
TW527590B (en) * 2000-04-25 2003-04-11 Matsushita Electric Industrial Co Ltd Compact disk, and the manufacturing method of the same, and the manufacturing device of compact disk
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
WO2002081443A1 (en) * 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
ES2393333T3 (es) * 2002-07-12 2012-12-20 Astellas Pharma Inc. Derivado de N-fenil-(2R,5S)dimetilpiperazina
CA2521619A1 (en) * 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
US20070015771A1 (en) * 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
NZ560917A (en) * 2005-03-31 2011-01-28 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
WO2008010073A8 (en) 2009-03-05
US20100004259A1 (en) 2010-01-07
WO2008010073A1 (en) 2008-01-24
AU2007274710A1 (en) 2008-01-24
JP2008044931A (ja) 2008-02-28
IL196417A0 (en) 2009-09-22
NO20090667L (no) 2009-02-11
ATE496894T1 (de) 2011-02-15
EP2044029B1 (en) 2011-01-26
ZA200901051B (en) 2010-01-27
CN101506172A (zh) 2009-08-12
AR062068A1 (es) 2008-10-15
DE602007012254D1 (de) 2011-03-10
TW200821293A (en) 2008-05-16
MX2009000508A (es) 2009-01-27
CA2657640A1 (en) 2008-01-24
JP4312243B2 (ja) 2009-08-12
EP2044029A1 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
JP4312243B2 (ja) (7S)−7−[(5−フルオロ−2−メチル−ベンジル)オキシ]−2−[(2R)−2−メチルピペラジン−1−イル]−6,7−ジヒドロ−5H−シクロペンタ[b]ピリジンの酒石酸塩
KR102815607B1 (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
KR102615828B1 (ko) Mct4 의 헤테로시클릭 저해제
JP2019517487A (ja) Ptpn11の複素環式阻害剤
JP4318744B2 (ja) シクロペンタピリジンおよびテトラヒドロキノリン誘導体
JP2012502067A (ja) 疾患の治療のためのヒスタミン受容体の複素環阻害剤
WO2008157500A1 (en) Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP2012502104A (ja) 疾患の治療のためのヒスタミン受容体に対するアミノピリミジン阻害剤
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20170096426A1 (en) Novel Tricyclic Modulators of Cannabinoid Receptors
CA2770767A1 (en) Bicyclic heteroaryl inhibitors of pde4
CN106349228A (zh) 取代的喹唑啉酮类化合物及其制备方法和用途
IL260178B2 (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl )-n-methyl-1h-3,2,1-triazole-4-carboxamide
KR20080021134A (ko) 5-ht1a 수용체의 피페라진-피페리딘 길항제 및 효능제
JP7777131B2 (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
HK1134810A (en) Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2[(2r)-2-methylpiperazin-1-yl]-6,7-dihydr(cyclopenta[b]pyridine
TW202304906A (zh) 高活性hpk1激酶抑制劑
CN101151249B (zh) 环戊吡啶及四氢喹啉衍生物
HK40130296A (en) Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions
JP2025537555A (ja) キノリンアミド構造を有するイソインドリノン誘導体及びその用途
CN120530113A (zh) 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20090212

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101022

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110915

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101022

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I